Novartis subsidiary Alcon has introduced new AcrySof IQ PanOptix toric presbyopia and astigmatism-correcting intraocular lens (IOL) for patients with pre-existing corneal astigmatism undergoing cataract surgery.
The new lens, which secured CE mark approval in last November, have been recently launched in Spain, Portugal and Chile.
AcrySof IQ PanOptix Toric IOL can be used for primary implantation in the capsular bag of the posterior chamber of the human eye for the visual correction of aphakia and pre-existing corneal astigmatism secondary to removal of a cataractous lens or clear lens.
The lens will be used for adult patients with and without presbyopia undergoing cataract surgery who want near, intermediate and distance vision.
They use the same trifocal optic as the AcrySof IQ PanOptix IOL on the front surface of the lens, while it includes astigmatic correction features of a toric IOL on the back surface.
According to the company, the new IOL can deliver an intermediate focal point at 60cm, a distance preferred by multiple patients for intermediate vision activities.
Alcon division head and CEO Mike Ball said: "The launch of the AcrySof IQ PanOptix Toric intraocular lens is a significant step forward in Alcon's presbyopia-correcting portfolio and extends our reach into the presbyopic population.
“This lens not only expands available options physicians have to provide value to their patients with astigmatism, it gives patients the visual clarity and increased independence to improve their current lifestyles.”